PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayAn international survey across 101 medical institutions has uncovered marked variations in how clinicians prevent and manage infectious complications in patients treated with bispecific antibodies and chimeric antigen receptor T-cell therapies. While both classes of immunotherapies have transformed the therapeutic landscape for hematologic malignancies, severe infections remain a primary contributor to patient morbidity and mortality. The multicenter investigation, conducted on behalf of the European Hematology Association Scientific Working Group on Infections in Hematology, evaluated antimicrobial prophylaxis, diagnostic surveillance, and the clinical management of therapy-induced immunodeficiency.
The surveyed facilities were predominantly academic tertiary hospitals, representing 80.2 percent of the participating centers worldwide. Despite caring for patients within specialized oncology and hematology settings, clinicians reported wide divergence in routine preventive strategies and monitoring standards. Researchers noted that contemporary clinical practices display notable heterogeneity, reflecting an absence of uniform clinical consensus regarding optimal supportive care pathways during and after these targeted cellular and antibody treatments.
Perceptions of infection patterns differed sharply depending on the underlying therapeutic modality administered. Among clinicians managing patients receiving bispecific antibodies, viral infections were perceived as the predominant complication, cited by 69.3 percent of respondents. In contrast, bacterial infections were perceived as the primary infectious threat following chimeric antigen receptor T-cell therapy, reported by 52.8 percent of surveyed practitioners. These contrasting perceptions emphasize the distinct biological impacts and clinical challenges posed by each treatment approach.
Prophylactic interventions showed strong uniformity for certain opportunistic pathogens but considerable divergence for others. Prophylaxis against Pneumocystis jirovecii pneumonia was nearly universal across institutions, implemented by 93.5 percent of centers administering bispecific antibodies and 97.5 percent of centers delivering chimeric antigen receptor T-cell therapy. Antiviral prophylaxis was also widely utilized. However, investigators observed an absence of consensus regarding the duration of these preventive regimens, with stopping criteria differing substantially between centers.
Disparities were even more pronounced when examining antibacterial and antifungal prophylaxis in patients treated with bispecific antibodies. Routine antibacterial prophylaxis was omitted by 86 percent of the centers administering bispecific antibodies, while antifungal prophylaxis was omitted by 38.7 percent of these facilities. Such widespread variation demonstrates divergent institutional thresholds for initiating preventive antimicrobial coverage in patients experiencing antibody-induced immune suppression.
Infection surveillance strategies also exhibited significant operational gaps, particularly regarding viral monitoring. Cytomegalovirus DNA surveillance differed markedly across programs, with one-third of centers administering bispecific antibodies reporting that they do not routinely monitor cytomegalovirus DNA levels. This surveillance gap stood in noticeable contrast to the high vigilance routinely maintained within chimeric antigen receptor T-cell treatment programs.
Survey participants underscored an urgent need for standardized, harmonized guidance to address these clinical variations. A clear majority of respondents identified better guidelines as an essential priority, comprising 72.3 percent of bispecific antibody centers and 52.8 percent of chimeric antigen receptor T-cell programs, alongside calls for improved diagnostic tools and multidisciplinary approaches. Participating centers highlighted a critical demand for risk-adapted protocols driven by measurable immune reconstitution rather than arbitrary fixed timelines.
The findings emphasize the pressing need for evidence-based guidance, especially given recent clinical data demonstrating prolonged hypogammaglobulinemia, substantial infection burdens per patient-month with continuously dosed bispecific antibodies, and the potential protective effect of immunoglobulin replacement therapy. The study investigators concluded that prospective clinical trials are warranted to systematically define optimal antimicrobial prophylaxis, pathogen surveillance, and immunoglobulin replacement strategies for these vulnerable patient cohorts.
Subject of Research: Infection prevention and management practices during bispecific antibody and CAR-T cell therapies
Article Title: Practice patterns, gaps, and priorities in infection management for patients receiving bispecific antibodies and CAR-T cell therapy – Results from the E-Impact survey of the EHA-SWG infections in hematology
Article References: Infante, M. S., Pagano, L., Einarsdóttir, S., Cornely, O. A., Salmanton-García, J., On behalf of E.-Impact investigators team, Mercier, T., Pantic, N., Luciani, F., Sprute, R., Niscola, P., Muchtar, E., Ibragimova, S., Yalcin, K., Forghieri, F., Segundo, L. Y. S., Petzer, V., Bhattacharjee, B., Seval, G. C., … De Jonge, N. A. (2026). Practice patterns, gaps, and priorities in infection management for patients receiving bispecific antibodies and CAR-T cell therapy – Results from the E-Impact survey of the EHA-SWG infections in hematology. Annals of Hematology. https://doi.org/10.1007/s00277-026-07358-6
Image Credits: AI Generated
DOI: 10.1007/s00277-026-07358-6
Keywords: bispecific antibodies, CAR-T cell therapy, infection management, hematologic malignancies, antimicrobial prophylaxis, Pneumocystis jirovecii, cytomegalovirus surveillance, hypogammaglobulinemia, immunoglobulin replacement, E-Impact survey, EHA-SWG, bacterial infections, viral infections, tertiary hospitals, clinical guidelines, immune reconstitution, antifungal prophylaxis, antibacterial prophylaxis


3 days ago
12




















English (US) ·
French (CA) ·